The 2017 FDA Regenerative Medicine Policy Framework and its 2020 – 2026 enforcement follow-through has changed what a U.S. clinic can legally offer, market, and combine. This is a plain-language operator's guide to the legal risk surface — informational only, not legal advice. Every clinic should have this reviewed by qualified regulatory counsel.
The single most important distinction: 361 vs 351
Human cell, tissue, and cellular/tissue-based products (HCT/Ps) are regulated under 21 CFR Part 1271. A product that meets all four Section 361 criteria — minimal manipulation, homologous use, no combination with another article (with narrow exceptions), and either autologous / first- or second-degree relative use or no systemic effect / metabolic dependence — does not require premarket approval. A product that misses any criterion is a Section 351 biologic and requires an IND / BLA.
Most of the enforcement activity of the last five years has been against clinics offering "stem cell" products that were, in FDA's view, 351 biologics without an IND — expanded MSC cultures, adipose-derived SVF for systemic indications, and umbilical-derived infusions marketed for non-homologous use.
Exosomes: not FDA-approved, and treated as biologic drugs
FDA has issued repeated public safety notifications stating that no exosome product is approved for any clinical indication and that exosomes are considered biologic drugs requiring IND authorization for investigational use. Clinics that advertise IV exosome infusions for anti-aging, long-COVID, autism, or chronic disease are the most visible current enforcement target. Topical or micro-channel adjunct use is a different risk profile than systemic infusion, but neither is FDA-approved.
Compounded peptides: a rapidly narrowing lane
- Peptides are FDA-regulated drugs. Compounded peptides must be prepared by a 503A or 503B pharmacy using a bulk substance that appears on FDA's permitted lists.
- Several previously-compounded peptides (including select GH secretagogues and research-only peptides) have been removed or restricted since 2023 – 2025 and should not be prescribed outside an approved pathway.
- "Research use only" peptides shipped to a clinic and injected into patients is unlawful practice — a common finding in state board actions.
Off-label use vs off-label promotion
A licensed physician may prescribe an FDA-cleared device or approved drug off-label for a patient in their professional judgment. What creates legal exposure is promotion of off-label use — website copy, social media claims, or paid ads that assert efficacy for uses beyond the labeled indications. This distinction is what turns a defensible clinical practice into an FDA warning letter or an FTC deceptive- marketing action.
State medical and pharmacy boards
Even where FDA action is unlikely, state medical boards discipline for standard-of-care deviations, inadequate informed consent, and untruthful advertising. State boards of pharmacy police the compounded-peptide supply chain and increasingly audit clinic relationships with out-of-state 503A pharmacies.
Marketing claims that reliably trigger action
- "Cures" or "reverses" a chronic disease.
- "Stem cell" used to describe a product without live, viable stem cells.
- Before/after imagery with unrealistic or non-consented depictions.
- Cost claims (e.g., "covered by insurance") that are not accurate for the product being sold.
- Efficacy claims for exosomes, IV NAD+, and unapproved peptide combinations.
A practical compliance checklist
- Written consent per product / procedure, updated annually, with off-label framing spelled out.
- Vendor documentation for every biologic: FDA registration, HCT/P eligibility, donor screening, lot-level release testing.
- A marketing review process — legal or regulatory counsel signs off on new claims before they go live.
- State-specific scope-of-practice review for NP / PA delegation.
- Pharmacy-of-record file for every compounded peptide the clinic prescribes.
How DRS operates inside this framework
DRS distributes only biologics from FDA-registered tissue banks operating under 21 CFR Part 1271, provides lot-level Certificates of Analysis, and refers peptide prescribing to 503A / 503B partners that operate inside current FDA guidance. We do not supply exosome, MSC, or peptide products for indications outside the regulatory framework described above.